VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8%
Fri, 22 Feb

VENUS REMEDIES has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

VENUS REMEDIES Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m931809691-14.6%-25.8%
Other incomeRs m1125-60.6%240.1%
TurnoverRs m933821695-15.3%-25.5%
ExpensesRs m754644643-0.1%-14.7%
Gross profitRs m17716547-71.3%-73.2%
DepreciationRs m8983830.0%-7.1%
InterestRs m8491943.4%12.1%
Profit before taxRs m53-125-4194.8%-2404.2%
TaxRs m0-5-60.0%
Profit after taxRs m58-119-1595.5%-2301.8%
Gross profit margin%19.020.46.9
Effective tax rate%0.0-161.64.4
Net profit margin%0.61.0-17.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 25.8% on a year-on-year (YoY) basis. The expenses were down by 14.7% YoY during the same period.
  • The company's operating profit declined by 73.2% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 6.9% in 3QFY19 as against 19.0% in 3QFY18.
  • Depreciation charges declined by 7.1% and finance costs increased by 12.1% YoY, respectively.
  • Other income increased by 240.1% YoY during the quarter.
  • Net profit for the quarter declined by 2301.8% YoY. Net profit margins during the quarter declined from 0.6% in 3QFY18 to -17.2% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 14.6% on a quarter-on-quarter (QoQ) basis. The expenses were down by 0.1% QoQ during the same period.
  • The company's operating profit declined by 71.3% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 6.9% in 3QFY19 as against 20.4% in 2QFY18.
  • Net profit for the quarter declined by 1595.5% QoQ, while net profit margins declined from 1.0% in 2QFY18 to -17.2% in 3QFY19.

To see how VENUS REMEDIES has performed over the last eight quarters, please visit here.

VENUS REMEDIES Share Price Performance

Over the last one year, VENUS REMEDIES share price has moved up from Rs 77.7 to Rs 31.0, registering a Loss of Rs 46.7 or around 60.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,571.8 (up 0.5%). Over the last one year it has moved down from 13,958.5 to 13,571.8, a gain of 387 points (down 2.8%).

Overall, the S&P BSE SENSEX is up 6.0% over the year.

Current Valuations

At the current price of Rs 31.0, the price to book value (P/BV) ratio of VENUS REMEDIES stands at 0.1 times.

Equitymaster requests your view! Post a comment on "VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8%". Click here!

  

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 19, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - GLENMARK PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS